Q-omics provides the consensus-scored NCOR1P3 profile across patient tissues and cancer cell-line models. NCOR1P3 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, NCOR1P3 is differentially expressed in 4, with the highest sampling consensus in STAD. Additionally, NCOR1P3 RNA expression shows 5,137 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight BRCA, and STAD as cancer lineages where NCOR1P3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NCOR1P3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NCOR1P3 survival associations across molecular data types. NCOR1P3 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NCOR1P3 RNA expression–survival associations across cancer types. High NCOR1P3 expression shows unfavorable associations in BRCA, KIRP, LUAD, HNSC, SARC and OV. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify BRCA as the clearest survival context for NCOR1P3 RNA expression.
This table summarizes NCOR1P3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for NCOR1P3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NCOR1P3 shows lower tumor expression in STAD and higher tumor expression in LIHC, HNSC and KIRC. The STAD box plot shows higher NCOR1P3 RNA expression in normal versus tumor tissue (log2 FC = −0.070, t-test p = .005).
This table shows molecular features associated with NCOR1P3 in patient tissues and cancer cell lines. In patient samples, NCOR1P3 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
